Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edurne Arriola

Showing results (41-50 of 90) with videos related to

Pageof 9
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 22, 2019
Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinomaJoan Gibert, Sergi Clavé, Max Hardy-Werbin, et al.
Archivos De Bronconeumologia|April 8, 2020
Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung AdenocarcinomaÁlvaro Taus, Laura Camacho, Pedro Rocha, et al.
Archivos De Bronconeumologia|December 24, 2013
Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancerÁlvaro Taus, Rafael Aguiló, Víctor Curull, et al.
International Journal of Molecular Sciences|February 13, 2025
The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung CancerAlbert Iñañez, Raúl Del Rey-Vergara, Fabricio Quimis, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2015
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensusFederico Cappuzzo, Denis Moro-Sibilot, Oliver Gautschi, et al.
Journal of Medical Economics|October 10, 2024
Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysisDolores Isla, Rosa Álvarez, María Arnal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2013
Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancerIsrael Cañadas, Federico Rojo, Álvaro Taus, et al.
Oncotarget|July 16, 2014
High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patientsIsrael Cañadas, Alvaro Taus, Iria González, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2016
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLCEdurne Arriola, Matthew Wheater, Ian Galea, et al.
Oncotarget|January 20, 2016
ROS1 copy number alterations are frequent in non-small cell lung cancerSergi Clavé, Javier Gimeno, Ana M Muñoz-Mármol, et al.
Pageof 9

Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
Lung Cancer (Amsterdam, Netherlands)|December 22, 2019
Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinomaJoan Gibert, Sergi Clavé, Max Hardy-Werbin, et al.
Archivos De Bronconeumologia|April 8, 2020
Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung AdenocarcinomaÁlvaro Taus, Laura Camacho, Pedro Rocha, et al.
Archivos De Bronconeumologia|December 24, 2013
Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancerÁlvaro Taus, Rafael Aguiló, Víctor Curull, et al.
International Journal of Molecular Sciences|February 13, 2025
The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung CancerAlbert Iñañez, Raúl Del Rey-Vergara, Fabricio Quimis, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2015
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensusFederico Cappuzzo, Denis Moro-Sibilot, Oliver Gautschi, et al.
Journal of Medical Economics|October 10, 2024
Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysisDolores Isla, Rosa Álvarez, María Arnal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2013
Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancerIsrael Cañadas, Federico Rojo, Álvaro Taus, et al.
Oncotarget|July 16, 2014
High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patientsIsrael Cañadas, Alvaro Taus, Iria González, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2016
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLCEdurne Arriola, Matthew Wheater, Ian Galea, et al.
Oncotarget|January 20, 2016
ROS1 copy number alterations are frequent in non-small cell lung cancerSergi Clavé, Javier Gimeno, Ana M Muñoz-Mármol, et al.
Pageof 9